Short interest in Milestone Pharmaceuticals Inc (NASDAQ:MIST) increased during the last reporting period, rising from 880.57K to 2.56M. This put 4.84% of the company's publicly available shares short.

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.